
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8908018/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Disruption of ClC-3, a Chloride Channel Expressed on Synaptic Vesicles, Leads to a Loss of the Hippocampus. Neuron, 2001, 29, 185-196.	8.1	480
2	Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease. Molecular and Cellular Proteomics, 2010, 9, 2424-2437.	3.8	434
3	Memory loss in Alzheimer's disease. Dialogues in Clinical Neuroscience, 2013, 15, 445-454.	3.7	393
4	Comparing and Combining Naltrexone and Acamprosate in Relapse Prevention of Alcoholism. Archives of General Psychiatry, 2003, 60, 92.	12.3	386
5	Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phosphoâ€Tau in patients with low―and high SF Aβ40 load. Journal of Neurochemistry, 2007, 101, 1053-1059.	3.9	237
6	MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease. PLoS ONE, 2015, 10, e0126423.	2.5	184
7	Metyrapone as Additive Treatment in Major Depression. Archives of General Psychiatry, 2004, 61, 1235.	12.3	163
8	Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Molecular Psychiatry, 2010, 15, 138-145.	7.9	156
9	Investigations on CXCL13 in Anti– <i>N</i> -Methyl- <scp>D</scp> -Aspartate Receptor Encephalitis. JAMA Neurology, 2015, 72, 180.	9.0	142
10	Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology, 2012, 78, 379-386.	1.1	141
11	Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type. Neurobiology of Aging, 2015, 36, 601-607.	3.1	125
12	Site-specific phosphorylation of the purified receptor for calcium-channel blockers by cAMP- and cGMP-dependent protein kinases, protein kinase C, calmodulin-dependent protein kinase II and casein kinase II. FEBS Journal, 1988, 178, 535-542.	0.2	120
13	Leptin: a modulator of alcohol craving?. Biological Psychiatry, 2001, 49, 782-787.	1.3	116
14	Elevation of β-Amyloid Peptide 2–42 in Sporadic and Familial Alzheimer's Disease and Its Generation in PS1 Knockout Cells. Journal of Biological Chemistry, 2001, 276, 42645-42657.	3.4	115
15	Modulation of the mineralocorticoid receptor as add-on treatment in depression: A randomized, double-blind, placebo-controlled proof-of-concept study. Journal of Psychiatric Research, 2010, 44, 339-346.	3.1	115
16	High prevalence of <scp>NMDA</scp> receptor IgA/IgM antibodies in different dementia types. Annals of Clinical and Translational Neurology, 2014, 1, 822-832.	3.7	114
17	Peptide Fingerprinting of Alzheimer's Disease in Cerebrospinal Fluid: Identification and Prospective Evaluation of New Synaptic Biomarkers. PLoS ONE, 2011, 6, e26540.	2.5	105
18	Pharmacological Relapse Prevention of Alcoholism: Clinical Predictors of Outcome. European Addiction Research, 2005, 11, 83-91.	2.4	96

#	Article	IF	CITATIONS
19	Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 4-10.	1.9	96
20	Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study. Neurobiology of Aging, 2008, 29, 812-818.	3.1	94
21	Amyloid β peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. Experimental Neurology, 2010, 223, 366-370.	4.1	92
22	Early and Differential Diagnosis of Dementia and Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2009, 27, 404-417.	1.5	90
23	Polyâ€ <scp>GP</scp> in cerebrospinal fluid links <i>C9orf72</i> â€associated dipeptide repeat expression to the asymptomatic phase of <scp>ALS</scp> / <scp>FTD</scp> . EMBO Molecular Medicine, 2017, 9, 859-868.	6.9	90
24	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 239-247.	1.9	89
25	Anxiolyticlike Effects of Atrial Natriuretic Peptide on Cholecystokinin Tetrapeptide–Induced Panic Attacks. Archives of General Psychiatry, 2001, 58, 371.	12.3	86
26	Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology, 2018, 91, e1390-e1401.	1.1	85
27	Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. Journal of Psychiatric Research, 2019, 113, 137-140.	3.1	81
28	Executive functioning in obsessive–compulsive disorder, unipolar depression, and schizophrenia. Archives of Clinical Neuropsychology, 2002, 17, 477-483.	0.5	73
29	The patient with dementia, the caregiver and the doctor: cognition, depression and quality of life from three perspectives. International Journal of Geriatric Psychiatry, 2008, 23, 604-610.	2.7	73
30	Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism. Journal of Psychiatric Research, 2005, 39, 545-551.	3.1	72
31	A multicenter <sup>1</sup> H-MRS study of the medial temporal lobe in AD and MCI. Neurology, 2009, 72, 1735-1740.	1.1	72
32	Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. PLoS ONE, 2018, 13, e0197329.	2.5	68
33	Impact of comorbid depressive symptoms on nonverbal memory and visuospatial performance in obsessive-compulsive disorder. Cognitive Neuropsychiatry, 2003, 8, 261-272.	1.3	66
34	Hypothalamic-Pituitary-Adrenocortical Axis Activity: A Target of Pharmacological Anticraving Treatment?. Biological Psychiatry, 2006, 60, 74-76.	1.3	60
35	Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. Alzheimer's Research and Therapy, 2017, 9, 84.	6.2	58
36	Leptin as a Possible Modulator of Craving for Alcohol. Archives of General Psychiatry, 2001, 58, 509.	12.3	55

#	Article	IF	CITATIONS
37	Central and Peripheral Administration of Atriopeptin Is Anxiolytic in Rats. Neuroendocrinology, 1997, 65, 210-215.	2.5	54
38	Asymmetrical Dimethylarginine Is Increased in Plasma and Decreased in Cerebrospinal Fluid of Patients with Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2008, 26, 58-64.	1.5	51
39	Is withdrawal-induced anxiety in alcoholism based on β-endorphin deficiency?. Psychopharmacology, 2002, 162, 433-437.	3.1	50
40	Modulation of sympathetic activity by corticotropin-releasing hormone and atrial natriuretic peptide. Neuropeptides, 2003, 37, 362-368.	2.2	49
41	Alcohol self-administration, craving and HPA-axis activity: an intriguing relationship. Psychopharmacology, 2002, 164, 239-240.	3.1	48
42	The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone. Life Sciences, 2003, 73, 1835-1845.	4.3	48
43	A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. Journal of Nutrition, Health and Aging, 2012, 16, 544-548.	3.3	48
44	Genetic interaction of <i>PICALM</i> and <i>APOE</i> is associated with brain atrophy and cognitive impairment in Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, S269-76.	0.8	47
45	Mineralocorticoid Receptor-Mediated Inhibition of the Hypothalamic-Pituitary-Adrenal Axis in Aged Humans. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2003, 58, B900-B905.	3.6	46
46	Dimensional structure of the Hamilton Depression Rating Scale in patients with obsessive–compulsive disorder. Psychiatry Research, 2004, 125, 171-180.	3.3	44
47	A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity. Journal of Psychopharmacology, 2018, 32, 668-677.	4.0	44
48	Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer's Disease. Journal of Proteome Research, 2020, 19, 1310-1318.	3.7	43
49	Association between fully automated MRI-based volumetry of different brain regions and neuropsychological test performance in patients with amnestic mild cognitive impairment and Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 335-344.	3.2	42
50	Involvement of NMDA receptors in alcohol-mediated behavior: mice with reduced affinity of the NMDA R1 glycine binding site display an attenuated sensitivity to ethanol. Biological Psychiatry, 2003, 53, 345-351.	1.3	41
51	Memory Concerns, Memory Performance and Risk of Dementia in Patients with Mild Cognitive Impairment. PLoS ONE, 2014, 9, e100812.	2.5	41
52	Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI. Neurology, 2015, 84, 1261-1268.	1.1	41
53	Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients – An Atlas-Based Volumetric MRI Study. Frontiers in Aging Neuroscience, 2018, 10, 45.	3.4	40
54	Atrial natriuretic hormone in lactate-induced panic attacks: mode of release and endocrine and pathophysiological consequences. Journal of Psychiatric Research, 1998, 32, 37-48.	3.1	36

#	Article	IF	CITATIONS
55	Use of proteomic methods in the analysis of human body fluids in <scp>A</scp> lzheimer research. Electrophoresis, 2012, 33, 3617-3630.	2.4	35
56	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. Neurobiology of Aging, 2014, 35, 2657.e13-2657.e19.	3.1	34
57	A Modified Reading the Mind in the Eyes Test Predicts Behavioral Variant Frontotemporal Dementia Better Than Executive Function Tests. Frontiers in Aging Neuroscience, 2018, 10, 11.	3.4	34
58	Suicide attempts with mirtazapine overdose without complications. Biological Psychiatry, 1998, 44, 925-926.	1.3	33
59	Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with <i>C9orf72</i> hexanucleotide repeat expansion. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 503-511.	1.9	33
60	Dimethylarginines, Homocysteine Metabolism, and Cerebrospinal Fluid Markers for Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 31, 751-758.	2.6	32
61	Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 349-356.	1.9	31
62	Adjunctive use of reboxetine in schizophrenia. European Psychiatry, 2004, 19, 366-369.	0.2	27
63	Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1090-1100.	6.4	26
64	C-type natriuretic peptide exerts effects opposing those of atrial natriuretic peptide on anxiety-related behaviour in rats. Brain Research, 1998, 792, 358-360.	2.2	25
65	No Effects of Antidepressants on Negative Symptoms in Schizophrenia. Journal of Clinical Psychopharmacology, 2013, 33, 686-690.	1.4	23
66	The Latent Dementia Phenotype l̂´ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 49, 547-560.	2.6	23
67	Clinico-genetic findings in 509 frontotemporal dementia patients. Molecular Psychiatry, 2021, 26, 5824-5832.	7.9	23
68	Quantifying progression in primary progressive aphasia with structural neuroimaging. Alzheimer's and Dementia, 2021, 17, 1595-1609.	0.8	22
69	Sleep Endocrine Effects of the 11-β-Hydroxysteroiddehydrogenase Inhibitor Metyrapone. Sleep, 2003, 26, 823-829.	1.1	21
70	Effects of treatment with acamprosate on $\hat{l}^2$ -endorphin plasma concentration in humans with high alcohol preference. Neuroscience Letters, 2006, 404, 103-106.	2.1	21
71	Amyloid-β Precursor Protein Modulates the Sorting of Testican-1 and Contributes to Its Accumulation in Brain Tissue and Cerebrospinal Fluid from Patients with Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2016, 75, 903-916.	1.7	18
72	Unraveling corticobasal syndrome and alien limb syndrome with structural brain imaging. Cortex, 2019, 117, 33-40.	2.4	17

#	Article	lF	CITATIONS
73	C-type natriuretic peptide exerts stimulatory effects on the corticotropin-releasing hormone-induced secretion of hormones in normal man. European Journal of Endocrinology, 1997, 136, 388-393.	3.7	16
74	Centrifugal Phe-Met-Arg-Phe-NH2-like immunoreactive innervation of the retina in a non-teleost bony fish, Lepisosteus osseus. Neuroscience Letters, 1999, 264, 33-36.	2.1	16
75	CCK-4: Psychophysiological conditioning elicits features of spontaneous panic attacks. Journal of Psychiatric Research, 2010, 44, 1148-1153.	3.1	16
76	Augmented Stress-Induced Alcohol Drinking and Withdrawal in Mice Lacking Functional Natriuretic Peptide-A Receptors. Alcohol and Alcoholism, 2010, 45, 13-16.	1.6	15
77	The applause sign in frontotemporal lobar degeneration and related conditions. Journal of Neurology, 2019, 266, 330-338.	3.6	15
78	α-Helical-corticotropin-releasing hormone reverses anxiogenic effects of C-type natriuretic peptide in rats. Brain Research, 2001, 893, 21-28.	2.2	14
79	Prolactin but not ACTH increases during sodium lactate-induced panic attacks. Psychiatry Research, 2002, 109, 201-205.	3.3	14
80	Overnight metyrapone and combined dexamethasone/metyrapone tests in post-traumatic stress disorder: preliminary findings. European Neuropsychopharmacology, 2004, 14, 337-339.	0.7	14
81	Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment—data from the Dementia Competence Network. Journal of Neural Transmission, 2022, 129, 477-486.	2.8	14
82	APOE-Dependent Phenotypes in Subjects with Mild Cognitive Impairment Converting to Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 37, 389-401.	2.6	13
83	Apolipoprotein E-dependent load of white matter hyperintensities in Alzheimer's disease: a voxel-based lesion mapping study. Alzheimer's Research and Therapy, 2015, 7, 27.	6.2	13
84	Acute effects of megestrol on the hypothalamic?pituitary?adrenal axis. Cancer Chemotherapy and Pharmacology, 2003, 52, 482-486.	2.3	10
85	Motor speech disorders in the nonfluent, semantic and logopenic variants of primary progressive aphasia. Cortex, 2021, 140, 66-79.	2.4	10
86	Natriuretic peptides and panic disorder: therapeutic prospects. Expert Review of Neurotherapeutics, 2003, 3, 381-386.	2.8	9
87	Copeptin – A potential endocrine surrogate marker of CCK-4-induced panic symptoms?. Psychoneuroendocrinology, 2017, 76, 14-18.	2.7	9
88	Comparative analysis of machine learning algorithms for multi-syndrome classification of neurodegenerative syndromes. Alzheimer's Research and Therapy, 2022, 14, 62.	6.2	9
89	Intraperitoneal Atrial Natriuretic Peptide Attenuates Anxiety-related Behaviour during Alcohol Withdrawal in Mice. Pharmacopsychiatry, 2014, 47, 97-100.	3.3	8
90	Alzheimer's disease: Elevated pigment epithelium-derived factor in the cerebrospinal fluid is mostly of systemic origin. Journal of the Neurological Sciences, 2017, 375, 123-128.	0.6	8

#	Article	IF	CITATIONS
91	A language-based sum score for the course and therapeutic intervention in primary progressive aphasia. Alzheimer's Research and Therapy, 2018, 10, 41.	6.2	8
92	Megestrol attenuates the hormonal response to CCK-4–induced panic attacks. Depression and Anxiety, 2006, 23, 139-144.	4.1	7
93	Capillary electrophoresis mass spectrometry as a potential tool to detect lithium-induced nephropathy: Preliminary results. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 673-678.	4.8	7
94	B-spline-based stereotactical normalization of brain FDG PET scans in suspected neurodegenerative disease: Impact on voxel-based statistical single-subject analysis. NeuroImage, 2010, 50, 994-1003.	4.2	7
95	A novel presenilin 1 mutation (Ala275Val) as cause of early-onset familial Alzheimer disease. Neuroscience Letters, 2014, 566, 115-119.	2.1	7
96	Differential effects to CCK-4-induced panic by dexamethasone and hydrocortisone. World Journal of Biological Psychiatry, 2012, 13, 526-534.	2.6	5
97	Mirtazapine-Induced Galactorrhea: A Case Report. Journal of Neuropsychiatry and Clinical Neurosciences, 2013, 25, E13-E14.	1.8	5
98	Genetic Risk Factors for Depression in Alzheimer's Disease Patients. Current Alzheimer Research, 2013, 10, 72-81.	1.4	5
99	Harman and norharman plasma levels in weaned alcoholics: correlations with depression and tobacco smoking. Addiction Biology, 2000, 5, 437-441.	2.6	4
100	Pharmacological treatment of non-Alzheimer dementias. Current Opinion in Psychiatry, 2006, 19, 642-648.	6.3	4
101	Influence of exogenous atrial natriuretic peptide on the nocturnal hypothalamic-pituitary-adrenal axis and sleep in healthy men. Psychoneuroendocrinology, 2010, 35, 1438-1445.	2.7	4
102	Predicting disease progression in behavioral variant frontotemporal dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12262.	2.4	4
103	Steroid-synthesis inhibition in depression: a good idea?. Lancet Psychiatry,the, 2016, 3, 92-93.	7.4	3
104	Overnight suppression of HPA axis after mineraolocorticoid receptor stimulation: A sleep endocrine study. Psychiatry Research, 2015, 227, 65-70.	3.3	2
105	Therapeutic Drug Monitoring of Naltrexone and 6β-Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference Ranges. Alcohol and Alcoholism, 2019, 54, 51-55.	1.6	2
106	MicroRNA Profiling of Alzheimer's Disease Cerebrospinal Fluid. Methods in Molecular Biology, 2018, 1750, 93-107.	0.9	2
107	A novel computerized algorithm to detect microstructural brainstem pathology in Parkinson's disease using standard 3 Tesla MR imaging. Journal of Neurology, 2014, 261, 1968-1975.	3.6	1
108	Recent advances in structural MRI in Parkinson's disease and atypical parkinsonian syndromes. Neurodegenerative Disease Management, 2012, 2, 517-533.	2.2	0

#	Article	IF	CITATIONS
109	Nonfluent Variant of Primary Progressive Aphasia With Right Hemisphere Atrophy – A Phenotype of Corticobasal Degeneration?. Movement Disorders Clinical Practice, 2015, 2, 420-421.	1.5	0
110	Atrial Natriuretic Peptide, the Hypothalamic–Pituitary–Adrenal Axis, and Panic Attacks. , 2019, , 177-186.		0
111	Uso auxiliar de la reboxetina en la esquizofrenia. European Psychiatry (Ed Española), 2005, 12, 107-110.	0.0	0
112	Proteomics as a New Tool for Biomarker-Discovery in Neuropsychiatric Disorders. , 2009, , 103-111.		0
113	Factors influencing atrophy progression in primary progressive aphasia. Alzheimer's and Dementia, 2021, 17, .	0.8	0
114	Memory Concerns, Memory Performance and Risk of Dementia in Patients with Mild Cognitive Impairment. , 2014, 9, e100812.		0